<DOC>
	<DOC>NCT01039675</DOC>
	<brief_summary>The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of inhaled GSK573719 and GW64244 compared to placebo, in subjects with COPD.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD</brief_title>
	<detailed_description>This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of the combination of GSK573719 (500mcg) Inhalation Powder and GW642444 (25mcg) Inhalation Powder administered once-daily via a novel dry powder inhaler (Novel DPI) over 28 days in subjects with COPD</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>A signed and dated written informed consent prior to study participation Males or females of nonchildbearing potential 40 or more years of age COPD diagnosis 10 packyears history or greater of cigarette smoking Postbronchodilator FEV1/FVC ratio of 0.70 or less Postbronchodilator FEV1 of 80% or less of predicted normal Current diagnosis of asthma Other significant respiratory disorders besides COPD, including alpha1 deficiency Previous lung resection surgery Significant abnormalities in chest xray presentation Use of oral steroids, antibiotics or hospitalization for a COPD exacerbation within 3 motnhs prior screening Any significant disease that would put subject at risk through study participation BMI greater than 35 Pacemaker Significantly abnormal ECG, Holter, or clinical lab finding (including Hepatitis B or C) Cancer Allergy or hypersensitivity to anticholinergics or inhaler excipients Diseases that would contraindicate the use of anticholinergics Use of oral corticosteroids within 6 weeks of screening Use of longacting betaagonists within 48 hours of screening Use of tiotropium within 14 days of screening Use of theophyllines or antileukotrienes within 48 hours of screening Use of shortacting bronchodilators within 4 hours of screening Use of investigational medicines within 30 days of screening Use of high dose inhaled corticosteroids Use of longterm oxygen therapy, CPAP or NIPPV Previous use of GSK573719 or GW642444</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>long-acting beta2-receptor agonist</keyword>
	<keyword>Safety and tolerability</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>long-acting muscarinic receptor antagonist</keyword>
	<keyword>COPD</keyword>
</DOC>